Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants

Growth Disorders Clinical Trial

— TRIUMF  

Official title:

Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants (6 to 18 Months)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03181178
• Other study ID #: Ghana Trial
• Status: Completed
• Phase: N/A
• First received: June 5, 2017
• Last updated: February 27, 2018
• Start date: February 2013
• Est. completion date: February 2015

Study information

• Verified date: February 2018
• Source: Nevin Scrimshaw International Nutrition Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prevention of malnutrition in infants and children requires access and intake of nutritious food starting at birth with exclusive breastfeeding for the first 6 months of life, breastfeeding in combination with complementary foods from 6-24 months of age, access to clean drinking water and sanitation, access to preventive and curative health care (including prenatal).

In Ghana, the Demographic and Health Survey of 2014 reports rates of stunting, wasting and underweight in children aged 0-59 months are 28%, 14% and 9% respectively. Furthermore, height for age starts dropping from age 4-6 months with children aged 6-23 months being more likely to be stunted (40%) than those below 6 months (4%). Infant and young child feeding data show that for breast-fed children ranging from 6 months through 35 months of age, cereals are predominantly the first foods introduced in the diet (6-8 months of age). As the child grows older, consumption of fruits rich in Vitamin A, other fruits and vegetables and meat, fish, poultry and eggs are reported by the mothers. The Demographic and Health Survey (DHS) found that the proportion of breast fed children aged 6-23 months who received a recommended variety of foods the minimum number of times per day increases with child's age from 28% in children 6-8 months to 50% in children aged 18-23 months.

The study objective is to examine the effect of providing a macro- and micro-nutrient fortified complementary food supplement (KokoPlusTM) on growth and nutritional status of Ghanaian infants.

Description:

The current study is a cluster randomized single blind intervention design study with three study arms that aimed to examine the effect of providing a macro- and micro-nutrient fortified complementary food supplement (KokoPlus) for a period of 12 months (starting at 6 months of age) on growth and nutritional status of Ghanaian infants at 18 months of age. KokoPlus was formulated using linear programming methodology based on formative and market analysis research findings.

The subjects in this cluster-randomized trial are from communities in three districts of the Central region in Ghana with high rates of moderate and severe acute malnutrition. A total of 38 communities will be randomly assigned to one of three groups using block randomization and another 11 (randomly selected) will be followed cross sectionally as part of a fourth/non intervention group (growth monitoring).

The total sample size is 1204. Sample size calculations were based on two outcome measures:

expected reduction in diarrheal morbidity and growth (improvements in height-for-age). Sample size estimates for detecting a 0.5 cm change in height in children provided a caloric and non caloric micronutrient supplement using a design effect of 2, power of 0.80, alpha of 0.05 and assuming an attrition rate of 15%, the required sample size per group was 301.

Mother-infant pairs will be recruited between infant age of 0 to 3 months to participate in monthly nutrition educations sessions and to encourage the women to continue exclusive breast feeding across all three groups. At 6 months of age, infants in each of the three groups were enrolled into the intervention study (upon receipt of informed consent). Data collection involves baseline, midline and endline measurements in the infants at 6, 12 and 18 months of age. In addition, participating mother-infant pairs will be visited weekly for delivery of the supplements and for morbidity monitoring and monthly for the measurement of anthropometry. Anthropometric measurements include: length (Infant/Child Shorr Height Board; Weigh and Measure, LLC ), weight (Seca 874 digital scale ), mid-upper arm circumference (MUAC) (Child MUAC Tape; Weigh and Measure, LLC), subscapular and triceps skinfolds (Holtain skinfold caliper ),head and chest circumference.

Data collection at baseline, midline and endline included one venous sample (3ml) from the infant, HemoCue (Model 301) measurement to assess severe anemia (7 The primary outcome of the study is the change in length for age Z-score from 6 to 18 months of age in infants in the KokoPlus group versus Micronutrient powder group and the Nutrition Education group. Data calculations included estimating anthropometric indices using the WHO (World Health Organization) 2006 growth reference charts using the WHO macro in STATA (18), computing the USAID Food and Nutrition Technical Assistance (FANTA) household insecurity access scores (HFIAS) (19) maternal body mass index (BMI), dietary diversity scores (20), and re-coding variables as required to binary and accounting for missing. Infant anthropometric indices calculated include length for age (LAZ) Z- score, weight for age Z-score (WAZ) and weight for length (WLZ score).

All analyses are intent to treat. Descriptive statistics (means, medians, standard deviations and standard errors) were computed. To verify the randomization assumption, any differences in mean values at baseline across three groups were tested using linear mixed effects regression analyses accounting for clustering. The effect of the supplement (KokoPlus, Micronutrients and Nutrition Education group) on different dependent variables across the intervention period will be tested using mixed effects regression analyses accounting for clustering and repeated measures. The dependent variables tested included change in LAZ between baseline and endline (primary outcome), change in LAZ on a monthly basis (primary outcome 2), change in WAZ, WLZ, serum hemoglobin (unadjusted and adjusted for inflammation), serum ferritin (unadjusted and adjusted for inflammation), serum zinc, serum cortisol, serum insulin growth factor-1 (IGF-1), serum retinol binding protein, C-reactive protein and alpha glycoprotein, prevalence of acute and chronic infection.

A cross-sectional assessment (anthropometry) will be conducted at baseline, midline and endline in 301 infants that are randomly selected from another set of communities (to be identified based on the same community selection criteria). These infants will not be followed longitudinally and the only measurements to be collected include weights and heights. Informed consent procedures will be similar to the three intervention arms. This group is a reference group only and cannot be included in any comparative analysis.

Monitoring of groups that receive a supplement will happen weekly. Compliance will be defined based on the number of supplement packets that are consumed per week. To assure that the mothers are compliant in using the supplement, they will be asked to return the empty supplement packages at the end of the week. Optimal compliance will be defined as consumption of at least 50% of the weekly samples. Supplements will be provided in plastic or paper bags with a clearly labelled household ID (identity number). Compliance and dose response to compliance will be reviewed in existing studies to determine minimum compliance required.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1204
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 6 Months

Eligibility

Inclusion Criteria:

1. Non pre-term

2. Singleton birth

3. Exclusively or predominantly breast fed up to time of recruitment

4. Parents planning to live in community for a period of 12 months and willing to participate in the trial for the entire period

5. Receive informed consent from both parents and/or caregivers or from mother alone if single

Exclusion Criteria:

1. Severely anemic (<7 g/dl) (to be referred to Community Health Post (CHP) for routine care on anemia as recommended by Ghana Health Service)

2. Severely malnourished (MUAC <110 mm) (to be referred to CHP with Community-based Management of Acute Malnutrition (CMAM) protocol) and/or use of CMAM protocol or below -2 standard deviations (SD) weight for age Z score

Related Conditions & MeSH terms

• Growth Disorders
• Infant Malnutrition
• Infant Nutrition Disorders
• Kwashiorkor
• Malnutrition
• Micronutrient Deficiency
• Morbidity;Infant
• Protein Malnutrition

Intervention

Dietary Supplement:
• Macro-micronutrient complementary food supplement
This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
• A micronutrient powder
This intervention provided a 1 g micronutrient powder with nutrition education

Behavioral:
• Nutrition education
This intervention provided nutrition education sessions

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
Nevin Scrimshaw International Nutrition Foundation	Ajinomoto USA, INC., Ghana Health Services, University of Cape Coast, University of Ghana

References & Publications (3)

de Pee S, Bloem MW. Current and potential role of specially formulated foods and food supplements for preventing malnutrition among 6- to 23-month-old children and for treating moderate malnutrition among 6- to 59-month-old children. Food Nutr Bull. 2009 Sep;30(3 Suppl):S434-63. Review. — View Citation

Ghana Statistical Service, Ghana Health Service, ICF Macro Ghana Demographic and Health Survey 2008, Accra, Ghana, p 512, 2009

Pan American Health Organization. Guiding Principles for Complementary Feeding of the Breast Fed Child p37, 2003

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in monthly length for age Z-score (monthly LAZ)	Change in length for age Z-score from 6 months to 18 months of age.	Measured on a monthly basis until 18 months of age
Secondary	Change in Serum Hemoglobin	Change in serum hemoglobin from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in Serum retinol binding protein	Change in serum retinol binding protein from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in serum transferrin receptors	Change from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in serum ferritin	Change from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in serum zinc	Change from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in Weight for age Z-score	This is the change in weight for age Z-score from 6 months to 18 months of age	Measured at baseline and then on a monthly basis for the duration of the intervention (12 months)
Secondary	Change in Weight for height Z-score	This is the change in weight for length Z-score from 6 months to 18 months of age	Measured at baseline and then on a monthly basis for the duration of the intervention (12 months)
Secondary	Prevalence of diarrhea	Prevalence of diarrhea over a 12 month period (duration of intervention)	Measured at baseline and then in a weekly surveillance for the duration of the intervention (12 months or 52 weeks)
Secondary	Prevalence of upper respiratory infections	Prevalence of respiratory infections over a 12 month period (duration of the intervention)	Measured at baseline and then in a weekly surveillance for the duration of the intervention (12 months or 52 weeks)
Secondary	Change in serum C-reactive protein	Change from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in serum alpha glycoprotein	Change from baseline to endline (6 months to 18 months)	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)
Secondary	Change in Head Circumference for age	This is the change in head circumference for age from 6 months to 18 months of	Measured at baseline and then on a monthly basis for the duration of the intervention (12 months)
Secondary	Change in MUAC (Mid Upper Arm Circumference)	This is the change in MUAC for age from 6 months to 18 months of age	Measured at baseline and then on a monthly basis for the duration of the intervention (12 months)
Secondary	Change in Plasma Amino Acid levels	This is the change in individual plasma amino acids from 6 months to 18 months	Baseline (6 months), Midline (12 months of age), Endline (18 months of age)